Clopidogrel Taw Pharma (previously Clopidogrel Mylan) European Union - English - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - clopidogrel hydrochloride - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease., - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy., , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke., , for further information please refer to section 5.1. , , ,

Clonazepam Rosemont 0.5 mg/5 ml oral solution Ireland - English - HPRA (Health Products Regulatory Authority)

clonazepam rosemont 0.5 mg/5 ml oral solution

taw pharma (ireland) limited - clonazepam - oral solution - 0.5 mg/5ml - benzodiazepine derivatives; clonazepam

Boots Pharmaceuticals Bite and Sting Relief Antihistamine 2% w/w Cream Ireland - English - HPRA (Health Products Regulatory Authority)

boots pharmaceuticals bite and sting relief antihistamine 2% w/w cream

taw pharma (ireland) ltd - mepyramine maleate - cream - 2 percent weight/weight - antihistamines for topical use; mepyramine

Boots Pharmaceuticals Decongestant 60mg Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

boots pharmaceuticals decongestant 60mg tablets

taw pharma (ireland) ltd - pseudoephedrine hydrochloride - tablet - 60 milligram(s) - sympathomimetics; pseudoephedrine

Boots Pharmaceuticals Diarrhoea Relief 2 mg Hard Capsules Ireland - English - HPRA (Health Products Regulatory Authority)

boots pharmaceuticals diarrhoea relief 2 mg hard capsules

taw pharma (ireland) ltd - loperamide hydrochloride - capsule, hard - 2 milligram(s) - antipropulsives; loperamide

Metformin Hydrochloride 500mg/5ml Oral Solution Ireland - English - HPRA (Health Products Regulatory Authority)

metformin hydrochloride 500mg/5ml oral solution

taw pharma (ireland) limited - metformin hydrochloride - oral solution - 500 mg/5ml - biguanides; metformin

Methadone Hydrochloride Sugar Free 1mg/1ml Oral Solution Ireland - English - HPRA (Health Products Regulatory Authority)

methadone hydrochloride sugar free 1mg/1ml oral solution

taw pharma (ireland) limited - methadone hydrochloride - oral solution - 1 milligram(s)/millilitre - drugs used in opioid dependence; methadone

Boots Ibuprofen and Codeine 200mg / 12.8 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

boots ibuprofen and codeine 200mg / 12.8 mg film-coated tablets

taw pharma (ireland) ltd - ibuprofen; codeine phosphate hemihydrate - film-coated tablet - 200 mg/12.8 milligram(s) - opioids in combination with non-opioid analgesics; codeine and ibuprofen

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) European Union - English - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome.non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event.prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.for further information please refer to section 5.1.

Amlodipine Taw Pharma 1 mg/ml or. susp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amlodipine taw pharma 1 mg/ml or. susp.

taw pharma (ireland) ltd. - amlodipine besilate 1,386 mg/ml - eq. amlodipine 1 mg/ml - oral suspension - 1 mg/ml - amlodipine besilate 1.386 mg/ml - amlodipine